Dogwood Therapeutics, Inc (NASDAQ:DWTX) Stock Short Interest Climbs 60.4%

Dogwood Therapeutics, Inc (NASDAQ:DWTX) saw a large increase in short interest in October. As of October 15th, there was short interest totaling 62,406 shares, an increase of 60.4% from the September 30th total of 38,895 shares. Based on an average daily trading volume, of 76,074 shares, the days-to-cover ratio is presently 0.8 days. Currently, 0.2% of the company’s stock are short sold.

Dogwood Therapeutics Price Performance

NASDAQ:DWTX traded down $0.03 during mid-day trading on Monday, reaching $1.25. The stock had a trading volume of 35,088 shares, compared to its average volume of 75,986. The business’s 50 day moving average is $1.68 and its 200 day moving average is $1.99. Dogwood Therapeutics has a fifty-two week low of $1.07 and a fifty-two week high of $7.04. The stock has a market cap of $42.49 million, a P/E ratio of -0.14 and a beta of 2.08.

Dogwood Therapeutics (NASDAQ:DWTX) last posted its earnings results on Thursday, August 13th. The company reported ($0.34) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.14) by ($0.20). Equities analysts expect that Dogwood Therapeutics will post -0.80 EPS for the current year.

Analyst Upgrades and Downgrades

DWTX has been the topic of a number of research reports. HC Wainwright reaffirmed a “buy” rating on shares of Dogwood Therapeutics in a research note on Wednesday, September 2nd. Weiss Ratings reissued a “sell (e+)” rating on shares of Dogwood Therapeutics in a research report on Thursday, October 22nd. One investment analyst has rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the company currently has an average rating of “Hold” and a consensus price target of $12.00.

About Dogwood Therapeutics

Dogwood Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing antiviral therapies for diseases associated with viral activation. The company’s programs are designed to address conditions for which persistent or reactivated viral activity may contribute to symptoms and disease progression.

Its lead investigational product, IMC-1, is an oral combination of the antiviral drug famciclovir and the anti-inflammatory drug celecoxib. The company has evaluated IMC-1 in fibromyalgia and has also investigated its potential use in other conditions, including symptoms associated with long COVID.